<DOC>
	<DOC>NCT02771379</DOC>
	<brief_summary>This study is a multicentre, prospective, non-interventional post-authorisation safety study (PASS) of the clinical outcomes for patients with LHON treated with Raxone®. No medication will be provided as part of this study. Raxone® will be obtained through commercial channels.</brief_summary>
	<brief_title>Post Authorisation Safety Study With Raxone in LHON Patients</brief_title>
	<detailed_description />
	<mesh_term>Optic Nerve Diseases</mesh_term>
	<mesh_term>Optic Atrophy, Hereditary, Leber</mesh_term>
	<mesh_term>Idebenone</mesh_term>
	<criteria>Patient prescribed Raxone® for the treatment of LHON; Patient has completed an Informed Consent Form (ICF) indicating that he/she (or a legally acceptable representative) has been informed of all pertinent aspects of the study and has agreed to participate in the study; Patient is not participating in any interventional study. No explicit exclusion criteria exist to avoid selection bias and to allow for documentation of routine clinical practice.</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>